Mer­ck KGaA pays $169M up­front in deal for Hen­grui’s PARP1 in­hibitor and ADC

Mer­ck KGaA is spend­ing €160 mil­lion ($169 mil­lion) up­front in a li­cens­ing and op­tion agree­ment for a pair of on­col­o­gy as­sets from Jiang­su Hen­grui Phar­ma­ceu­ti­cals …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER